Spatial Distribution and Birth Prevalence of Congenital Heart Disease in Iran: A Systematic Review and Hierarchical Bayesian Meta-Analysis

Roghaye Farhadi Hassankiadeh, Annette Dobson AM, Somayeh Rahimi, Abdollah Jalilian, Volker J Schmid, Behzad Mahaki

DOI: https://doi.org/10.34172/ijhpm.2024.7931

Article History:
Received Date: January 9, 2023
Accepted Date: April 6, 2024
epublished Author Accepted Version: April 7, 2024

Copyright: © 2024 The Author(s); Published by Kerman University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Please cite this article as: Farhadi Hassankiadeh R, Dobson AA, Rahimi S, Jalilian A, Schmid VJ, Mahaki B. Spatial distribution and birth prevalence of congenital heart disease in Iran: a systematic review and hierarchical Bayesian meta-analysis. Int J Health Policy Manag. 2024;x(x):x–x. doi: 10.34172/ijhpm.2024.7931

This PDF file is an Author Accepted Manuscript (AAM) version, which has not been typeset or copyedited, but has been peer reviewed. IJHPM publishes the AAM version of all accepted manuscripts upon acceptance to reach fast visibility. During the proofing process, errors may be discovered (by the author/s or editorial office) that could affect the content, and we will correct those in the final proof.
Manuscript Type: Meta-Analysis

Spatial Distribution and Birth Prevalence of Congenital Heart Disease in Iran: A Systematic Review and Hierarchical Bayesian Meta-Analysis

Roghaye Farhadi Hassankiadeh1, Annette Dobson AM2, Somayeh Rahimi3, Abdollah Jalilian4, Volker J Schmid5, Behzad Mahaki*1

1. Department of Biostatistics, School of Health, Kermanshah University of Medical Sciences, Kermanshah, Iran.
2. School of Public Health, University of Queensland, Herston, Brisbane, QLD, Australia.
3. Department of Clinical Biochemistry, Kermanshah University of Medical Sciences, Kermanshah, Iran.
4. Department of Statistics, Razi University, Kermanshah, Iran.
5. Department of Statistics, Ludwig-Maximilians-University, Munich, Germany.

Correspondence to: Behzad Mahaki; behzad.mahaki@gmail.com

Abstract

Background: This study aimed to comprehensively analyze the overall congenital heart disease (CHD) prevalence in live births and children in Iran, along with evaluating the spatial distribution of CHD birth prevalence across various geographical regions within the country.

Methods: A Bayesian hierarchical meta-analysis (PROSPERO 2022: CRD42022331281) was performed to determine the pooled prevalence. A systematic search was conducted using ISI Web of Science, Science Direct, PubMed, IranDoc, SID, and Magiran until October 4, 2023. Cross-sectional and cohort studies in both English and Persian languages, focusing on the age range of 0-10 years, were considered for the study population. The study quality was evaluated using the Agency for Healthcare Research Quality (AHRQ) Risk of Bias tool. Heterogeneity was assessed by I² and τ² statistics, and publication bias by Egger’s and Begg’s tests.

Results: The meta-analysis included 62 studies, revealing an overall CHD prevalence of 2.5 per 1000 births. Over time, CHD birth prevalence in Iran has consistently increased. Spatial distribution analysis, including spatial autocorrelation and local spatial autocorrelation, indicated no spatial clustering (P-value = 0.46) or aggregation (P-value = 0.65) among Iran’s provinces. Geographic disparities were significant ((P-value = 0.000), with the northern and eastern regions showing the highest and lowest CHD prevalence, respectively.

Conclusion: The overall CHD prevalence in Iran is lower than global rates, but it continues to rise. Furthermore, there are variations in birth prevalence among different regions of Iran. Environmental, genetic, socioeconomic, and diagnostic accessibility differences are possibly involved in regional variation. The limitations like heterogeneity among studies, the potential inaccuracy of reports due to limited use of accurate diagnostic methods in some studies, and the absence of population-based models to investigate prevalence, underscore the urgent need for standardized diagnostic approaches, and the utilization of population-wide birth defect registries to accurately assess CHD prevalence in Iran.

Keywords: Bayesian Hierarchical Meta-Analysis; Congenital Heart Diseases; Prevalence; Iran; Spatial Analysis
Background
Congenital anomalies are a series of disorders that occur during embryonic life that could be life-threatening to infants. Congenital heart disease (CHD) accounts for 28% of all birth anomalies and is a significant global health problem. CHD involves various structural or functional abnormalities affecting the heart or large intrathoracic vessels, which are classified into distinct subtypes based on specific cardiac abnormalities. While congenital heart disease is present at birth, it may initially remain clinically silent and only manifest symptoms later in life. The cardiac lesions are categorized into mild, moderate, and severe. Most mild lesions do not require intervention or may heal spontaneously. However, severe or critical lesions (25-35% of CHD) require early intervention or surgery and can be associated with morbidity and mortality. Early diagnosis through echocardiography and subsequent medical and surgical interventions, have significantly improved the prognosis for severe CHD in developed nations. However, in parts of the developing world, access to treatment for more severe conditions remains unavailable.

Advancements in medical science have enabled more CHD patients to reach adulthood, presenting a new challenge in the form of grown-up congenital heart disease patients and adding to the global health burden. Early detection of Congenital anomalies reduces the significant economic and social burden on families and society, and elevates the life expectancy of patients. Consequently, identifying cardiac abnormalities during fetal development becomes imperative to mitigate their impact.

The prevalence of CHD varies among populations, diverse geographic regions, and over time. The most feasible indicator for CHD occurrence is its prevalence per 1000 live births. In a meta-analysis study, it was estimated that the average global prevalence of congenital heart disease in live births, spanning the years 2010 to 2017, was 9.4 per 1000 live births. Notably, Asia exhibited a higher prevalence compared to other global regions during this period. Furthermore, there is a significant difference in the prevalence of CHD between developed and developing countries. However, a comprehensive and accurate assessment of CHD prevalence is lacking for numerous countries, including Iran. Iran is a country with ethnic and racial diversity and various geographical regions, there could be inequality in the access and quality of healthcare services. So, it is important to describe the distribution of prevalence of congenital heart disease in different geographical areas in this country. Studies conducted in Iran estimate a wide range of prevalence of CHD, with different figures between zero and...
26.48 cases per 1000 live births\textsuperscript{10-16}. Gaining insights into the distribution of congenital heart disease in each country is imperative for understanding its etiology, identifying high-risk populations, and efficiently implementing targeted services for prevention and management. Therefore, we conducted a systematic review and meta-analysis based on available studies up to 2023 to provide a comprehensive nationwide overview of the reported prevalence and spatial distribution of congenital heart disease in Iran.

**Methodology**

This review protocol was registered on PROSPERO\textsuperscript{1}2022: CRD42022331281. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) guideline checklist was followed in this review (Supplementary PRISMA 2020 Checklist). We defined PICOST (Population, Intervention [Exposure], Comparison, Outcome, Study design, and Time)\textsuperscript{17} to ensure that the assessment contained only the most relevant studies.

**Inclusion criteria**

1) Participants: This research included studies that investigated the prevalence of CHD among participants from birth to 10 years old. At first, our selection criteria focused on studies investigating CHD prevalence at birth. Upon thorough assessment, the majority of these studies concentrated on the age group of 0-1 years, except for two studies covering broader age ranges of 0-8 years and 0-10 years. These two specific studies were incorporated due to their valuable information into the spatial patterns of CHD prevalence at birth. 2) Study design: cross-sectional and cohort studies. 3) Language: Studies published in either Persian or English language. 4) Outcomes: the prevalence of CHD was outcome. 5) Publication year: Systematic search was done without any time limit until 4 October 2023

**Exclusion criteria**

1) Studies such as reviews, comments, or books. 2) Studies examining the prevalence of CHD in special populations, such as the Down syndrome population, and so on. 3) Studies that reported CHD prevalence exclusively in schoolchildren and adults, without considering the prevalence at birth, were not included.

**Search strategies**

\textsuperscript{1} International prospective register of systematic reviews
We systematically searched the English language databases, including ISI Web of Science, Science Direct, PubMed, and Scopus, and Iranian databases, including Iranian Research Institute for Information Science and Technology (IranDoc), Scientific Information Database (SID), Magiran, to identify related and available articles until October 4, 2023. The search strategy involved the utilization of Medical Subject Headings (MeSH) terms, combined with keywords and Boolean operators. The search concepts included terms related to "congenital", "heart", "cardiac", "cardiovascular", "disease", "defect", "anomaly", "anomaly" "disorders", prevalence, "epidemiology", "prevalence", "prevalence", "Iran" and "Iranian". All articles were searched without any time limit and the search strategy is provided in the supplement (Supplementary Search Strategy).

**Data Extraction and Quality Assessment**

Two authors (R.F. and S.R.) independently conducted the data extraction. The information gathered included details such as the first author, year of publication, study location (Province), demographic characteristics (sex), study period, number of patients with CHD used to calculate birth prevalence, total study population, CHD subtype, diagnostic tool and language of publication (English or Persian). To ensure consistency and reliability, both reviewers worked independently throughout the extraction process, and any discrepancies were resolved through discussion and consensus.

The quality of the study was assessed using the Agency for Healthcare Research and Quality (AHRQ) Risk of Bias tool\(^\text{18}\). The use of AHRQ to assess the quality of cross-sectional/prevalence studies has been recommended in several studies\(^\text{18-20}\). AHRQ tools are also used to assess the quality of cohort studies. All the studies included in this study were cross-sectional, and the cohort study in Iran was not utilized to determine the CHD prevalence. An item was given a score of "0" if the response was "no" or "unclear", and "1" if the response was "yes". The maximum scale was 11, and the scores were categorized as low quality (1-3), moderate quality (4-7), and high quality (8-11)\(^\text{19,21,22}\). All of the studies that were included had an AHRQ score, with a range of 7 to 11 (Supplementary File for Quality Assessment with AHRQ).

**Statistical Methods**

First, a hierarchical Bayesian meta-analysis was conducted to model the log odds (logit) pooled birth prevalence with a 95% confidence interval (CI) (see Supplementary model). Then heterogeneity between the studies was examined using the I\(^2\) index and the τ\(^2\) test.
The $I^2$ index is the percentage of effect size variability that is not due to sampling error, and $\tau^2$ indicates the variation of the true effect sizes. In fixed effect models, $\tau^2 = 0$ is assumed, which indicates there is no evidence of heterogeneity (threshold values of for heterogeneity of true effect sizes $\tau^2$: 0.25 (moderate), 0.5 (substantial), 1 (high) and 2 (very high))\textsuperscript{23-25}. Also $I^2 > 0.75$ was assumed as high-value for heterogeneity \textsuperscript{26,27}.

Subgroup sensitivity analyses were conducted, with a focus on sex, geographic regions, and length of follow-up, to find possible factors of heterogeneity. In addition to Egger's (Test for Funnel Plot Asymmetry) and Begg's tests, a funnel plot was also used to estimate publication bias. Bayesian hierarchical methods allow for the investigation of between-study heterogeneity and within-study variability. They enable the estimation of the posterior distribution of two parameters (effect and heterogeneity), evaluation of joint and marginal posterior probability distributions, and so on \textsuperscript{28}.

In the time-trend analyses, studies were defined in three-year groups dependent on the year of investigation. The first and second groups included more than 3 years since only three and one study were collected in those periods, respectively. Time trends were plotted using the Moving Average smoothing technique. Factors such as sex, geographic region, and length of follow-up were considered in the subgroup analysis. The overall estimate was then compared to the estimates of the different subgroups using a proportion test. The forest plot showed log(odds) and 95% credible intervals for each study and the pooled results from this meta-analysis.

**Spatial Autocorrelation**

Spatial autocorrelation analysis describes how spatial data are interdependent \textsuperscript{29}. The distribution pattern of the birth prevalence of CHD can be expressed as clustered, dispersed, or random countrywide \textsuperscript{30}. Global and local spatial autocorrelations analyses were conducted. To analyze the distribution of CHD prevalence across all provinces, a global spatial autocorrelation method was used. The spatial autocorrelation of province locations and the prevalence of CHD was assessed using the Global Moran's I method. The range of the Moran index $I$ is -1 to 1. If the data are consistent with the null hypothesis that $I = 0$, the pattern of distribution can be considered to be random. $I > 0$ implies that the data is clustered, and $I < 0$ implies that the data is over-dispersed \textsuperscript{31}. Local spatial autocorrelation was used to investigate the CHD prevalence distribution mode in Iran. Getis-Ord $G$ can be regarded as the index of hot spot analysis and shows that the high or low values are clustered. If $G > 0$ and $Z > 1.96$, ...
Iran would be considered a hotspot area, which would indicate that the CHD prevalence distribution inside the Iran was spatially clustered with p-value < 0.05. We fitted the Bayesian hierarchical model and calculated the log odds of CHD birth prevalence. logodds are symmetric around zero, which makes them easier to work with mathematically. We then converted these estimates (log odds) back to the prevalence (Supplementary model).

Software
Data were analyzed using SPSS16, MS Excel, ArcGIS 10.2, and R4.1.3 software. The R packages used included metafor and bayesmeta.

Results
Characteristics of the included studies
The literature search identified a total of 3798 records for screening. After duplicates were removed, 3433 unique records were screened by titles and abstracts. A total of 109 studies were assessed for full-text eligibility after removing obviously irrelevant articles based on evaluation of their titles and abstracts. Finally, 62 studies remained for further analysis (Supplementary data and Figure 1). These studies included a total of 6,303,428 births and 8,989 individuals with CHD. Only 20 of the studies explicitly mentioned the use of echocardiography as a diagnostic method, while 4 studies did not specify their diagnostic methods. The remaining studies employed a combination of other diagnostic methods. As shown in Figure 2, we stratified CHD prevalence studies according to time of publication. From 1979 to 1990, only two studies were available, leading us to categorize these 12 years into one category. For the subsequent years, we categorized studies based on their publication time at 3-year intervals. Most of the studies are related to the years 2011 to 2013, and 38 studies (60%) were reported from 2010.
Figure 2. PRISMA Flow diagram for selection of studies
Figure 2. The number consists of studies on the prevalence of CHD, based on the time of publication, of 3-year groups by 2023.

**Birth prevalence of CHD over time**

Based on the Results of the Bayesian hierarchical meta-analysis, the birth prevalence of CHD in Iran from (years of publication) 1979-2023 was 2.50 (95% CI: 1.83, 3.37) per 1000. Figure 3 displays the time-trend analyses of CHD prevalence using a simple moving average with a 3-interval. This figure represents a general pattern of increase over the last decades. The highest prevalence was in 2012-2014 (4.89 (95% CI= 2.81 to 8.27) per 1000). The heterogeneity of log (Odds) between studies was observed ($I^2= 99.4%$; $\tau^2=1.26$, 95% CI=1.1 to 1.5).
**Figure 3.** Iranian overall birth prevalence of CHD over time. Timeline of the reported birth prevalence of all CHD from 1979 to 2023. The squares show each period's calculated birth prevalence values, while the blue line depicts the time trend.
**Birth prevalence of CHD in different geographical regions**

Remarkable geographical variations were observed in the total prevalence of CHD ($\chi^2 = 34516$, df = 4, P-value = 0.000). Figure 4 shows the pooled prevalence of CHD in various provinces of Iran using the classification based on geometrical intervals. The highest birth prevalence was found in Ilam, Mazandaran and Ardabil (6.69, 6.63, and 6.43, per 1000, respectively) and were shown on the map in dark green. The lowest were found in Hormozgan (0.09 per 1000) and was shown on the map in light green (Figure 4 and Table1). It is worth noting that no studies were found in the three provinces. To estimate these provinces, we categorized Iran's provinces into five regions: North, East, Central, West, and South. We then conducted a meta-analysis by grouping these regions to determine the prevalence of CHD in each region. Finally, we used this information to estimate the spatial distribution of CHD prevalence by substituting the corresponding prevalence for each of the three provinces. The overall estimated CHD prevalence in North, East, West, South, and Central regions was 5.17, 1.33, 2.35, 4.73, and 2.11 per 1000, respectively. (Supplementary Table).

**Spatial analysis**

To obtain an estimate of the spatial distribution of the prevalence of CHD, global spatial autocorrelation was estimated using Moran’s I. The Moran’s I test result showed no spatial clustering in the distribution of CHD prevalence in various provinces ($I = -0.11$, P-value $= 0.46$). Similarly, for local spatial autocorrelation, the Getis G statistic was not statistically significant different from zero (p-value $= 0.65$), indicating no evidence of spatial aggregation (Supplementary Figure1).
Figure 4. Geographical distribution of prevalence of CHD at the province level in Iran during 1979-2023
<table>
<thead>
<tr>
<th>Geographical regions</th>
<th>Number of Studies</th>
<th>Pooled prevalence</th>
<th>Lower bound of pooled prevalence (95% CI)</th>
<th>Upper bound of pooled prevalence (95% CI)</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alborz</td>
<td>3</td>
<td>2.19</td>
<td>0.80</td>
<td>4.82</td>
<td>36-38</td>
</tr>
<tr>
<td>Ardebil</td>
<td>2</td>
<td>6.43</td>
<td>0.79</td>
<td>26.08</td>
<td>39,40</td>
</tr>
<tr>
<td>Bushehr</td>
<td>1</td>
<td>0.82</td>
<td>0.00</td>
<td>14.77</td>
<td>41</td>
</tr>
<tr>
<td>Chahar Mahaal and Bakhtiari</td>
<td>1</td>
<td>0.2</td>
<td>0.01</td>
<td>3.68</td>
<td>42</td>
</tr>
<tr>
<td>East Azarbayegan</td>
<td>8</td>
<td>2.46</td>
<td>1.71</td>
<td>3.53</td>
<td>43-50</td>
</tr>
<tr>
<td>Fars</td>
<td>1</td>
<td>4.63</td>
<td>1.09</td>
<td>19.46</td>
<td>51</td>
</tr>
<tr>
<td>Gilan</td>
<td>1</td>
<td>5.54</td>
<td>1.68</td>
<td>18.71</td>
<td>52</td>
</tr>
<tr>
<td>Golestan</td>
<td>6</td>
<td>4.73</td>
<td>1.89</td>
<td>9.29</td>
<td>53-57</td>
</tr>
<tr>
<td>Hamadan</td>
<td>0</td>
<td>(Estimated)</td>
<td>2.35</td>
<td>1.63</td>
<td>-</td>
</tr>
<tr>
<td>Hormozgan</td>
<td>1</td>
<td>0.09</td>
<td>0.01</td>
<td>1.66</td>
<td>58</td>
</tr>
<tr>
<td>Ilam</td>
<td>1</td>
<td>6.69</td>
<td>1.49</td>
<td>29.89</td>
<td>59</td>
</tr>
<tr>
<td>Isfahan</td>
<td>5</td>
<td>4.07</td>
<td>1.49</td>
<td>11.21</td>
<td>60-64</td>
</tr>
<tr>
<td>Kerman</td>
<td>1</td>
<td>4.45</td>
<td>1.47</td>
<td>13.93</td>
<td>65</td>
</tr>
<tr>
<td>Kermanshah</td>
<td>1</td>
<td>3.37</td>
<td>1.13</td>
<td>10.25</td>
<td>66</td>
</tr>
<tr>
<td>Khorasan-e-Razavi</td>
<td>2</td>
<td>0.66</td>
<td>0.16</td>
<td>1.93</td>
<td>67,68</td>
</tr>
<tr>
<td>Khuzestan</td>
<td>3</td>
<td>5.62</td>
<td>3.91</td>
<td>7.77</td>
<td>69-71</td>
</tr>
<tr>
<td>Kohgiluyeh and Boyer-Ahmad</td>
<td>0</td>
<td>(Estimated)</td>
<td>4.73</td>
<td>3.05</td>
<td>-</td>
</tr>
<tr>
<td>Kurdistan</td>
<td>0</td>
<td>(Estimated)</td>
<td>2.35</td>
<td>1.63</td>
<td>-</td>
</tr>
<tr>
<td>Lorestan</td>
<td>1</td>
<td>4.12</td>
<td>1.41</td>
<td>12.44</td>
<td>72</td>
</tr>
<tr>
<td>Markazi</td>
<td>1</td>
<td>0.25</td>
<td>0.01</td>
<td>3.33</td>
<td>10</td>
</tr>
<tr>
<td>Mazandaran</td>
<td>1</td>
<td>6.63</td>
<td>2.03</td>
<td>21.88</td>
<td>73</td>
</tr>
<tr>
<td>North Khorasan</td>
<td>1</td>
<td>1.07</td>
<td>0.33</td>
<td>3.61</td>
<td>68</td>
</tr>
<tr>
<td>Qazvin</td>
<td>1</td>
<td>6.08</td>
<td>2.09</td>
<td>18.34</td>
<td>74</td>
</tr>
<tr>
<td>Province</td>
<td>Well</td>
<td>Muh</td>
<td>MTH</td>
<td>DTH</td>
<td>Notes</td>
</tr>
<tr>
<td>-------------------</td>
<td>------------</td>
<td>------</td>
<td>------</td>
<td>-----</td>
<td>---------------------</td>
</tr>
<tr>
<td>Qom</td>
<td>1</td>
<td>1.95</td>
<td>0.64</td>
<td>6.12</td>
<td>75</td>
</tr>
<tr>
<td>Semnan</td>
<td>1</td>
<td>0.15</td>
<td>0.03</td>
<td>0.69</td>
<td>76</td>
</tr>
<tr>
<td>Sistan and Baluchistan</td>
<td>1</td>
<td>0.34</td>
<td>0.02</td>
<td>6.06</td>
<td>77,78</td>
</tr>
<tr>
<td>South Khorasan</td>
<td>2</td>
<td>1.59</td>
<td>0.86</td>
<td>3.02</td>
<td>79,80</td>
</tr>
<tr>
<td>Tehran</td>
<td>10</td>
<td>2.09</td>
<td>0.86</td>
<td>4.97</td>
<td>16,36-38,75,81-85</td>
</tr>
<tr>
<td>West Azarbayjan</td>
<td>1</td>
<td>4.51</td>
<td>0.50</td>
<td>24.36</td>
<td>86</td>
</tr>
<tr>
<td>Yazd</td>
<td>5</td>
<td>2.96</td>
<td>1.73</td>
<td>4.87</td>
<td>87-90</td>
</tr>
<tr>
<td>Zanjan</td>
<td>1</td>
<td>0.39</td>
<td>0.13</td>
<td>1.25</td>
<td>91</td>
</tr>
</tbody>
</table>

**Note:** The study of two provinces of Alborz and North Khorasan overlaps with Tehran and Khorasan-e-Razavi provinces, and three provinces were estimated to be neighboring provinces (refer to the limitations section).
**Birth prevalence of CHD by sex**

Although gender is not reported in all studies, a total of 12 studies (242970 births) identified the birth prevalence of total CHD in different sexes, including 720 male and 585 female patients\(^{16,54,56,60,62,72,74,75,79,84,89,92}\). In males, the overall CHD prevalence was 2.9 (95% CI = 1.5 to 5.5), while in females the birth prevalence was 2.4 (95% CI = 1.3 to 4.73) \((\chi^2 = 45.472, \text{ df} = 1, \text{ P-value} = 0.000)\).

**Birth prevalence of CHD by length of follow-up**

The length of follow-up of included studies was divided into less than 12 months (9 studies), between 12 and 24 months (26 studies), and more than 24 months follow-up (27 studies). The duration or length of the follow-up study in this investigation refers to the period during which all infants born were examined to identify those with congenital heart malformations. Length of follow up analyses indicated a rise from 0.71 per thousand in studies with less than 12 months, to 3.05 per thousand in studies with more than 24 months follow-up \((P<0.001)\).

**Table 2.** Iranian overall birth prevalence of CHD /1000 over the course length of follow up.

<table>
<thead>
<tr>
<th>length of follow-up</th>
<th>Pooled birth prevalence per 1000 (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less than 12 months</td>
<td>0.71 (0.34,1.47)</td>
</tr>
<tr>
<td>12 to 24 months</td>
<td>1.9 (1.1,3.2)</td>
</tr>
<tr>
<td>More than 24 months</td>
<td>3.05 (1.78, 5.02)</td>
</tr>
</tbody>
</table>

**Birth prevalence of major subtypes of CHD**

The birth prevalence of subtypes reported in the studies is presented in Table 1. Only 17 studies (involving 4569 individuals with CHD and 823333 births) focused on identifying the CHD prevalence and its most common subtypes\(^{16,39,44,54-57,60-62,70,72,78,84,89,92,93}\). The rest of studies had a more general focus on the prevalence of congenital anomalies. The total pooled birth prevalence of CHD for studies that reported CHD subtype was 5.71 per 1000 births (95% CI= 3.51 to 9.29) \((\text{Supplementary Figure2 and Supplementary Table})\).

The subtype’s prevalence with 95% confidence intervals was calculated for these 17 studies \((\text{Table 3})\). A Bayesian meta-analysis was used to calculate the pooled birth prevalence, considering the events of each subgroup and the total number of births in the meta-analysis formula. However, when calculating the percentages, the total number of congenital heart diseases was used instead of the total number of births. The most frequent types of CHD were
found to be Ventricular Septal Defect (VSD) (19.78% of total prevalence), Atrial Septal Defect (ASD) (16.11% of total birth prevalence), and patent ductus arteriosus (PDA) (12.56% of total birth prevalence), respectively. In total, the first six subtypes included 59.30% of the total burden of CHD.

Table 3. The birth prevalence and percentage of specific CHD subtypes.

<table>
<thead>
<tr>
<th>Major subtypes of CHD</th>
<th>Abbreviation(s)</th>
<th>Number of studies</th>
<th>Pooled birth prevalence per 1000 (95% CI)</th>
<th>Percentage of birth prevalence subtypes, % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ventricular Septal Defect</td>
<td>VSD</td>
<td>14</td>
<td>1.17[0.6,2.44]</td>
<td>19.78[12.78,29.11]</td>
</tr>
<tr>
<td>Atrial Septal Defect</td>
<td>ASD</td>
<td>13</td>
<td>0.91[0.51,1.56]</td>
<td>16.11[11.05,21.59]</td>
</tr>
<tr>
<td>Patent Ductus Arteriosus</td>
<td>PDA</td>
<td>12</td>
<td>0.72[0.41,1.2]</td>
<td>12.56[10.43,14.93]</td>
</tr>
<tr>
<td>Tetralogy of Fallot</td>
<td>TOF</td>
<td>14</td>
<td>0.35[0.17,0.69]</td>
<td>6.00[3.42,9.98]</td>
</tr>
<tr>
<td>Transposition of the Great Arteries</td>
<td>TGA</td>
<td>7</td>
<td>0.24[0.1,0.55]</td>
<td>3.9[1.95,6.85]</td>
</tr>
<tr>
<td>Pulmonary Stenosis</td>
<td>PS</td>
<td>9</td>
<td>0.22[0.12,0.38]</td>
<td>3.14[1.93,5.17]</td>
</tr>
<tr>
<td>Coarctation of Aorta</td>
<td>CoA</td>
<td>4</td>
<td>0.19[0.08,0.4]</td>
<td>2.96[1.48,5.37]</td>
</tr>
<tr>
<td>Pulmonary Atresia</td>
<td>PA</td>
<td>4</td>
<td>0.13[0.06,0.26]</td>
<td>2.19[1.25,3.39]</td>
</tr>
<tr>
<td>Tricuspid Regurgitation</td>
<td>TR</td>
<td>4</td>
<td>0.12[0.046,0.3]</td>
<td>1.85[0.78,4.07]</td>
</tr>
<tr>
<td>Aortic Stenosis</td>
<td>AS</td>
<td>5</td>
<td>0.10[0.05,0.18]</td>
<td>1.34[0.84,2.77]</td>
</tr>
<tr>
<td>Hypoplastic Left Heart Syndrome</td>
<td>HLHS</td>
<td>2</td>
<td>0.08[0.03,0.2]</td>
<td>1.25[0.55,2.5]</td>
</tr>
<tr>
<td>Condition</td>
<td>Abbreviation</td>
<td>Prevalence</td>
<td>95% CI</td>
<td>RR</td>
</tr>
<tr>
<td>---------------------------</td>
<td>--------------</td>
<td>------------</td>
<td>--------------</td>
<td>-------</td>
</tr>
<tr>
<td>Mitral Regurgitation</td>
<td>MR</td>
<td>0.07</td>
<td>[0.03, 0.13]</td>
<td>0.92</td>
</tr>
<tr>
<td>Atrioventricular Septal Defect</td>
<td>AVSD</td>
<td>0.06</td>
<td>[0.04, 0.1]</td>
<td>0.89</td>
</tr>
<tr>
<td>Mitral Valve Prolapse</td>
<td>MVP</td>
<td>0.05</td>
<td>[0.03, 0.11]</td>
<td>0.78</td>
</tr>
<tr>
<td>Patent Foramen Ovale</td>
<td>PFO</td>
<td>0.05</td>
<td>[0.03, 0.11]</td>
<td>0.78</td>
</tr>
<tr>
<td>Pulmonary Hypertension</td>
<td>PH</td>
<td>0.05</td>
<td>[0.02, 0.11]</td>
<td>0.78</td>
</tr>
<tr>
<td>Pulmonary Regurgitation</td>
<td>PR</td>
<td>0.05</td>
<td>[0.02, 0.11]</td>
<td>0.78</td>
</tr>
</tbody>
</table>

**Heterogeneity, subgroup analyses, publication bias, and sensitivity analysis**

In our study, within the pooled prevalence for subgroups defined by sex, geographic region, length of follow-up, and major subtypes of CHD, the heterogeneity indices for the birth prevalence of CHD were high ($I^2 > 75\%$, $\tau^2 > 1$) (See Heterogeneity plot in Supplementary Figure 3 and Supplementary Table). Publication bias was not statistically significant in the meta-analysis ($P$-value Begg’s = 0.97, $P$-value Egger’s < .0001). (See funnel plot and in Supplementary Figure 4). Moreover, the robustness of the Bayesian analysis was verified with various sensitivity analyses. Sensitivity analyses using several weakly informative prior distributions demonstrated the robustness of these selections.

**Discussion**

In this study, our aim was to calculate the birth prevalence of CHD in Iran and investigate its geographical distribution. Our meta-analysis included 62 studies, revealing an overall CHD prevalence of 2.5 per 1000 births. This estimate of CHD prevalence was lower than the global prevalence (8.2 per 1000) and the Asian prevalence (9.3 per 1000) $^1,^7$. This difference can likely be attributed to a combination of the design of the main studies, the selection of the studied population, various diagnostic methods, environmental and genetic influences, socio-economic factors, and differences in monitoring models (hospital-based/ population-based) $^{32}$. All studies included in our meta-analysis were hospital-based monitoring models. Zhao et al., in their meta-analysis, revealed that population-based monitoring models showed a significantly higher prevalence of CHD compared to hospital-based models. In their
predominantly hospital-based study, the overall prevalence of CHD in China was estimated to be 2.5 per 1000, consistent with the findings of our study. In studies specifically focusing on congenital heart disease and reporting its subtypes (17 studies), the estimated total birth prevalence of CHD was 5.94 (95% Confidence Interval (CI) = 3.47 to 10.83) per 1000 births. Notably, 71% of these studies employed echocardiography, which enhances the capability to detect minor defects compared to physical examination. It is worth mentioning that, in the majority of the 62 studies where we calculated the overall prevalence, the diagnosis was based on physical examination. Consequently, the calculated overall prevalence of CHD in Iran might be underestimated. The diagnostic method employed plays a pivotal role in estimating prevalence rates, emphasizing the urgent need to enhance skills and awareness within the healthcare system for accurate CHD diagnosis. Achieving this goal involves increasing the presence of medical specialists and improving access to advanced diagnostic tools, particularly echocardiography. In addition, the use of more accessible and cost-effective methods such as pulse oximetry can also help in the early detection of CHD cases. Furthermore, 40% of the studies were conducted before 2010. This suggests that we need new studies with more accurate study designs. Moreover, the conducted studies did not include data on the number of cases that did not survive due to severe heart disease during the fetal and neonatal periods. Additionally, pregnancy screening and evaluations of aborted fetuses may increase the frequency. So, by addressing these factors, we can improve the accuracy of CHD prevalence estimates.

In our study, spatial autocorrelation (global and local autocorrelation) showed that there was no spatial clustering across provinces and no aggregation characteristics within provinces in the overall birth prevalence of CHD. On the other hand, significant geographic differences were identified. Compared with other regions, the northern and eastern regions had the highest and lowest CHD prevalence, respectively. While there is no clear explanation, the difference could be influenced by various environmental, genetic factors, socioeconomic factors, years of study, and variation in the methodologies employed to assess CHD prevalence across different provinces of Iran. Also, due to an inadequate healthcare system and follow-up, lack of accessible diagnostic tools, CHD prevalence may be underestimated in some studies and provinces. It should be noted that only 6 eligible studies were related to eastern Iran, which all studies were published before 2014. Also, in these studies, the diagnostic tool was not reported exactly and echocardiography was not used for diagnosis.
We also found that the CHD birth prevalence was higher in males versus females, which is consistent with some previous studies \(^{19,97}\). The precise processes underlying males' higher CHD birth prevalence remain unknown and deserve additional investigation \(^{98}\).

Subgroup analysis on the length of follow-up indicated that studies with a length of follow-up greater than 24 months had a significantly greater birth prevalence of CHD. One of the reasons for the heterogeneity was the length of follow-up, which is also mentioned in the study by Zhao et al. \(^{32}\).

The overall reported birth prevalence of CHD has increased over time, rising from 1.58 per 1,000 births in 1979-1990 to 2.5 per 1,000 births in 2021-2023 respectively. It seems that industrialization and urbanization have an effect on the occurrence of CHD, indeed, the increase of environmental risk factors (air quality, organic solvents, groundwater pollution, etc.) over time may increase the risk of congenital heart defects \(^{32,99}\). On the other hand, in recent years, due to the improvement of diagnostic and screening methods, the diagnosis of CHD has increased \(^{10}\). This may lead to an increase in the birth prevalence of CHD and specific subtypes such as VSD, ASD, PDA, TOF, PS, and TGA over time \(^{100}\). The results of our study also showed that these six common subtypes constitute 59.30% of the total burden of CHD.

**Policy implications**

There are two main implications of the current findings for health policy and data collection. First, while following regional estimates, country-specific criteria can be utilized to plan and implement health intervention programs to address and reduce the burden of congenital abnormalities. These programs must take into account the rise in healthcare costs brought on by congenital defects, particularly in terms of long-term care. Second, analysis of data coverage revealed that there are fewer health records available for newborns and certain gestational periods. So, these results will help create a database for subsequent research on the etiology and racial, ethnical and environmental components differences in CHD in the region. The results can inform important modifications in health policies for the enhancement of therapeutic and diagnostic capabilities \(^{16,54}\).

**Strengths and limitations of this study**

This study has several strengths. First, this meta-analysis is the first to systematically collect published studies on the spatial and total birth prevalence of CHD in Iran. We used all the studies in which the birth prevalence of CHD was reported. Therefore, it has added knowledge about the prevalence of the disease and spatial distribution of the Iranian population by
examining data from 31 provinces and 62 studies and has identified the major subtype’s birth prevalence. Second, we conducted a Bayesian hierarchical meta-analysis to calculate a pooled CHD prevalence. The Bayesian hierarchical random effect model is an alternative to the classical meta-analysis for estimating the precise pooled effect size, particularly when there are few studies. In this study, subgroups such as CHD subtypes were identified in only a few studies. Forth, in the Bayesian hierarchical meta-analysis, the credible interval is slightly wider than in the classical meta-analysis, and the results will be more reliable. As a result, compared to classical meta-analysis, the Bayesian hierarchical meta-analysis is more conservative and more consistent.

This review has substantial limitations. First, there was significant heterogeneity in our review. Although subgroup analyses were performed by geographic regions, periods, and length of follow-up, there is still significant heterogeneity between subgroups. On the other hand, heterogeneity was unavoidable because of the difference in the design of original studies, selection of study population, different diagnosis methodologies, physician abilities among participating hospitals, maternal age, and gestational age. Second, some studies did not have annual prevalence data. For instance, they reported the prevalence for the entire period from 2004 to 2012 and separately for the years 2004 to 2006, 2007 to 2009, and 2010 to 2012. So, we adopted the strategy that this study could have been counted three times when performing the time trend analysis. This may have had a minimal effect on the results of the time trend analysis. Third, because there is not sufficient data in some province and some years, the result should be interpreted with caution. For instance, in the administrative divisions of Iran, the number of provinces has increased from 28 to 31 in the last two decades, so we equated the prevalence of new provinces for which we did not have with the prevalence of the provinces that previously belonged to the same area (2 provinces). On the other hand, no study was found for three provinces. Therefore, based on geographical regions, we divided Iran’s provinces into 5 regions: North, East, Central, West and South. We performed a meta-analysis by sub-grouping these 5 regions and calculated the prevalence of each region, then substituted the corresponding prevalence of these provinces to obtain the spatial distribution of CHD prevalence.

Conclusions: The overall prevalence of CHD in Iran is lower than the global rate, but it has generally increased from 1975 to 2023. Furthermore, there were significant geographical differences among the different regions of Iran. This observation can likely be attributed to factors such as various environmental and genetic, socio-economic, and availability of
healthcare and diagnostic facilities that should be measured or controlled in future studies. Moreover, while the total number of studies was adequate, the prevalence of CHD was found to be scattered and sparse in some provinces and some years. Therefore, it is imperative to develop comprehensive population-based prospective birth defect registries that encompass the entire population of Iran to accurately ascertain the prevalence of CHD.

**Disclaimers**
The views presented in this article are those of the authors.

**Authors’ contributions**
BM and RFH provided to the conception and design of the study. RFH contributed to the first draft of the manuscript text, the statistical analysis and quality control. RFH and SR separately extracted the data from each article. BM, AD, SR, AJ, and VJ. S revised this study and made significant recommendations. All authors reviewed, revised, and approved the work's submitted version.

**References**


41. Pouladfar GR, Malahzadeh AR. The prevalence of minor congenital anomalies and normal variations in neonates in bushehr port. *Iranian South Medical Journal (ISMJ)*. 2005;8(1):--.


90. Rafati S. *Examining the frequency and types of congenital anomalies of newborns born in hospitals in Yazd province during the years 2016-2022*. Tehran: Faculty of Medicine, Shahed University; 2023.
93. Amiri Simkouii F, Jamshidi M, Behjati Ardakani M, Toosi F, Alipour MR, Namayandeh SM. Comparative study of pulse oximetry, physical examination and echocardiography results in